Compare Vertiv Holdings Co (VRT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertiv Holdings Co vs Viatris Inc — how do they compare? Vertiv Holdings Co trades at $244.92 (market cap $93.83B), while Viatris Inc trades at $17.2 (market cap $20.03B). The key difference: Vertiv Holdings Co is far larger — about 4.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Vertiv Holdings Co for 39 Days and Viatris Inc for 57 Days on average.
| VRT | VTRS | |
|---|---|---|
Market Cap | $93.83B | $20.03B |
Volume | 5,855,911 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $376.23 | $18.27 |
52-Week Low | $149.83 | $9.74 |
Typical Hold Time | 39 Days | 57 Days |
Enterprise Value | $94.06B | $32.15B |
Dividend Yield | 0.1% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertiv Holdings (VRT) trades at $244.94, down 0.63% for the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company demonstrates strong fundamental performance with Q2 2026 EPS of $1.52 beating estimates of $1.42, continuing a pattern of earnings surprises. Revenue growth remains robust at $11.5B projected for 2026, while profitability metrics show improvement with net income margin expanding to 15.09%. Recent news highlights VRT's strategic positioning in AI data center infrastructure, though legal investigations following a stock drop present near-term concerns.
The investment outlook remains positive based on strong analyst consensus with 95% buy ratings and a $364.94 price target representing 49% upside potential. Key opportunities include VRT's leadership in data center cooling solutions amid AI infrastructure growth, while risks involve potential securities law violations investigation and competitive pressures in the industrial technology sector. The company's cash flow generation remains healthy with $1.2B net cash flow projected for 2026, supporting continued business expansion.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
